Citation Method of Allocation Blinding Loss to Use of Ceasing study Reporting all Funding source randomisation concealment follow-up early for benefit outcome where results required Weir et al. Unclear (no High risk (no Participants: <15% Low risk Unclear No (Low risk) All outcomes Novartis (2010) methods given) method of Not blinded, (loss to follow reported, low Pharmaceuticals concealment high risk up risk Corporation, used) between unclear Providers: not groups), low blinded, high risk risk Outcome assessors: not blinded, high risk
Citation Method of randomisation Allocation concealment Blinding Loss to follow-up Use of where required Ceasing study early for benefit Reporting all outcome results Funding source Weir et al. (2010) Unclear (no methods given) High risk (no method of concealment used) Participants: Not blinded, high risk Providers: not blinded, high risk Outcome assessors: not blinded, high risk <15% Low risk (loss to follow up between groups), low risk Unclear No (Low risk) All outcomes reported, low risk Novartis Pharmaceuticals Corporation, unclear
Sodium%20Supporting%20Document%201%20%20Systematic%20Literature%20Review.docx